Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
117 studies found for:    "beta thalassemia"
Show Display Options
Rank Status Study
21 Completed Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia
Condition: Beta Thalassemia
Interventions: Drug: HQK-1001;   Drug: Placebo
22 Completed Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
Condition: Beta-Thalassemia
Interventions: Drug: ICL670;   Drug: deferoxamine
23 Unknown  Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major
Condition: Beta-Thalassemia
Intervention: Drug: deferiprone
24 Completed Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand
Condition: Beta Thalassemia Intermedia
Intervention: Drug: sodium 2,2 dimethylbutyrate
25 Completed Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major
Conditions: Beta Thalassemia Major;   Congenital Anemias
Intervention: Genetic: GCSF, Central venous line placement, Stem cell Collection (leukapheresis)
26 Withdrawn An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old
Condition: β-thalassemia Major
Intervention: Drug: Deferasirox
27 Recruiting A Study Evaluating the Efficacy and Safety of LentiGlobin BB305 Drug Product in Beta-Thalassemia Major and Sickle Cell Disease
Conditions: Beta-Thalassemia Major;   Sickle Cell Disease
Intervention: Genetic: LentiGlobin BB305 Drug Product
28 Recruiting Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major
Condition: Beta-Thalassemia Major
Interventions: Drug: Basiliximab,;   Drug: cyclosporine A;   Drug: Methotrexate;   Drug: Mycophenolate mofetil
29 Completed Efficacy Study of the Use of Sequential DFP-DFO Versus DFP
Conditions: Beta-Thalassemia;   Thalassemia Major
Interventions: Drug: Deferiprone (DFP) and Deferoxamine (DFO);   Drug: Deferiprone (DFP)
30 Completed Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
Conditions: Beta-thalassemia;   Myelodysplastic Syndromes;   Fanconi Syndrome;   Anemia, Diamond-Blackfan;   Anemia, Aplastic
Intervention: Drug: Deferasirox
31 Unknown  Therapeutic Effects of Silymarin in Patients With B-thalassemia Major
Conditions: Beta-thalassemia Major;   Iron Overload
Interventions: Drug: Silymarin (LEGALON);   Drug: Placebo
32 Recruiting Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.
Conditions: Beta Thalassemia Major;   Beta Thalassemia Intermedia
Interventions: Drug: Dose level 1a;   Drug: Dose level 1b;   Drug: Dose level 2;   Drug: dose level 3;   Drug: dose level 4;   Drug: dose level 5
33 Recruiting Long Term Outcomes in β Thalassemia Major
Condition: Thalassemia Major
Intervention:
34 Completed Perceptions of Thalassemia Major in Singapore: An Exploratory Study of Stigma
Condition: Thalassemia Major
Intervention:
35 Unknown  Prevalence Of Microalbuminuria Among Children Suffering From Sickle Cell Nephropathy and Sickle Cell/Beta-Thalassemia
Conditions: Sickle Cell Anemia;   Beta-Thalassemia;   Microalbuminuria
Intervention: Other: No intervention
36 Completed Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
Condition: Thalassemia Major
Intervention: Drug: Amlodipine
37 Recruiting Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia
Conditions: Iron Overload;   Beta-Thalassemia
Intervention: Drug: SP-420
38 Recruiting Post Hematopoietic Stem Cell Transplantation
Condition: Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major
Intervention: Drug: ICL670
39 Active, not recruiting B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals
Conditions: Asplenia;   β-thalassemia Major
Intervention: Biological: PCV13
40 Recruiting Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major
Condition: Thalassemia Major
Intervention: Genetic: unrelated CB following haplo-identical hematopoietic stem cells transplantation

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years